PTPRA

Across TCGA pan-cancer cohorts, PTPRA mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PTPRA data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PTPRA mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PTPRA expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and LSCC are the cancer types where PTPRA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.922	0.641	.004	10	view →
GBM	OS	Median	All	0.963	0.757	.007	9	view →
LSCC	DFS	Tertile	III,IV	1.000	0.547	.015	6	view →
CCRCC	OS	Tertile	III,IV	0.978	0.259	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PTPRA–LUAD (OS)

Open the LUAD breakdown →